Barclays Portfolio holdings
Barclays PLC, founded in 1690 by goldsmith bankers in London, is a British multinational financial institution headquartered in London, operating as one of the world’s oldest banks with a significant presence in investment banking, retail banking, and wealth management. Managing billions in assets, Barclays serves millions of customers globally through its retail arm (notably in the UK) and its investment banking division, which excels in trading, mergers and acquisitions, and capital markets, competing with Wall Street giants. The bank has navigated challenges like the 2008 financial crisis—opting for private funding over a government bailout—and has since focused on restructuring, digital innovation, and sustainable finance initiatives. With a rich history and a modern global footprint, Barclays remains a key player in both UK and international financial markets.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Gilead Sciences
GILD
|
+$479M |
| 2 |
Meta Platforms (Facebook)
META
|
+$465M |
| 3 |
State Street Consumer Discretionary Select Sector SPDR ETF
XLY
|
+$445M |
| 4 |
Kenvue
KVUE
|
+$434M |
| 5 |
Micron Technology
MU
|
+$431M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVIDIA
NVDA
|
+$3.24B |
| 2 |
Apple
AAPL
|
+$1.9B |
| 3 |
Microsoft
MSFT
|
+$1.56B |
| 4 |
PepsiCo
PEP
|
+$1.34B |
| 5 |
JPMorgan Chase
JPM
|
+$1.34B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 19.7% |
| 2 | Financials | 7.47% |
| 3 | Consumer Discretionary | 6.7% |
| 4 | Communication Services | 6.02% |
| 5 | Healthcare | 4.93% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
4451
Golub Capital BDC
GBDC
$3.42B
| $120K | ﹤0.01% |
+8,852
| New | +$123K |
|
4452
TMC The Metals Company
TMC
$1.97B
| $120K | ﹤0.01% |
19,431
+14,668
| +308% | +$103K |
|
4453
Cadeler
CDLR
$2.24B
| $119K | ﹤0.01% |
+6,423
| New | +$120K |
|
4454
PUT
Arcus Biosciences
RCUS
$3.66B
| $119K | ﹤0.01% |
+5,000
| New | +$102K |
|
|
GOOS
4455
Canada Goose Holdings
GOOS
$856M
| $119K | ﹤0.01% |
9,193
-398,405
| -98% | -$5.3M |
|
4456
Microbot Medical
MBOT
$113M
| $119K | ﹤0.01% |
59,377
+59,376
| +5,937,600% | +$141K |
|
4457
American Well
AMWL
$221M
| $118K | ﹤0.01% |
24,047
+9,705
| +68% | +$46.8K |
|
4458
CALL
TotalEnergies
TTE
$195B
| $118K | ﹤0.01% |
+1,800
| New | +$114K |
|
4459
Lakeland Industries
LAKE
$120M
| $117K | ﹤0.01% |
13,289
+388
| +3% | +$5.45K |
|
4460
BARK
BARK
$96.8M
| $116K | ﹤0.01% |
9,641
-108
| -1% | -$1.6K |
|
|
FSP
4461
Franklin Street Properties
FSP
$45.8M
| $116K | ﹤0.01% |
122,577
+11,489
| +10% | +$13.4K |
|
4462
ReNew
RNW
$2.5B
| $115K | ﹤0.01% |
20,409
| – | – |
|
|
MAPS
4463
DELISTED
WM TECHNOLOGY INC A
MAPS
| $115K | ﹤0.01% |
139,680
+14,844
| +12% | +$14.6K |
|
|
ZFEB
4464
Innovator Equity Defined Protection ETF - 1 Yr February
ZFEB
$152M
| $115K | ﹤0.01% |
4,536
-3,501
| -44% | -$87.9K |
|
4465
BRC Group Holdings
RILY
$292M
| $115K | ﹤0.01% |
24,609
+17,274
| +236% | +$85.5K |
|
4466
AbCellera Biologics
ABCL
$2.99B
| $115K | ﹤0.01% |
33,547
+2,649
| +9% | +$11.8K |
|
4467
Innovator US Equity Buffer ETF September
BSEP
$217M
| $114K | ﹤0.01% |
+2,319
| New | +$113K |
|
4468
Playboy Inc
PLBY
$163M
| $114K | ﹤0.01% |
60,651
+59,710
| +6,345% | +$97.6K |
|
4469
Cellebrite
CLBT
$4B
| $114K | ﹤0.01% |
6,305
+3,582
| +132% | +$64.3K |
|
4470
Virco
VIRC
$92.2M
| $113K | ﹤0.01% |
17,665
+2,495
| +16% | +$17.4K |
|
|
XAPR
4471
FT Vest U.S. Equity Enhance & Moderate Buffer ETF - April
XAPR
$29.7M
| $113K | ﹤0.01% |
3,095
-1,922
| -38% | -$69.3K |
|
|
VSNT
4472
Versant Media Group
VSNT
$5.12B
| $113K | ﹤0.01% |
+2,500
| New | +$116K |
|
4473
Instil Bio
TIL
$50.8M
| $112K | ﹤0.01% |
10,145
+3,995
| +65% | +$59.1K |
|
|
MNTN
4474
MNTN Inc
MNTN
$854M
| $111K | ﹤0.01% |
9,326
+8,944
| +2,341% | +$129K |
|
4475
Seer Inc
SEER
$119M
| $111K | ﹤0.01% |
60,717
+52,982
| +685% | +$108K |
|
Similar funds
Barclays's Q4 2025 Portfolio in Review
As of Q4 2025, Barclays held 5,847 positions worth $417B, down 9.7% from $461B the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Barclays withdrew a net $49.1B in Q4 2025, closing 641 positions and reducing 1,715 holdings. Its most notable exit was Verona Pharma, an estimated $149M position sold in full.
By sector, the portfolio is most concentrated in Technology at 20% of assets, down from 20% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Barclays opened a new position in The Magnum Ice Cream Company N.V. worth $156M.
- Barclays's largest Q4 2025 buy was The Magnum Ice Cream Company N.V.: 9,862,859 shares worth $156M.
- Barclays added most to Gilead Sciences in Q4 2025, an estimated $479M increase.
- Barclays's biggest Q4 2025 reduction was NVIDIA, cutting an estimated $3.24B.
- Barclays fully exited Verona Pharma in Q4 2025, selling an estimated $149M.
- Barclays's ten largest holdings make up 35% of its $417B portfolio in Q4 2025.
- Barclays opened 403 new positions and closed 641 in Q4 2025.
- Barclays's portfolio value fell 9.7% quarter-over-quarter to $417B.
Based on Barclays's 13F filing for Q4 2025, filed 13 Feb 2026.